2020-03-10 22:03
“We are pleased with our results in the analytical validation, which is part of our FDA application and so far meet the criteria we have set. However, a component supplier has had delivery delays which means that we now anticipate being able to...
2020-01-16 08:00
“We are very pleased that these results, which were initially presented at the AACR annual meeting 2019, are published in the renowned journal Clinical Cancer Research. The data shows that DiviTum® can be used to evaluate the treatment efficacy...
2019-12-06 08:00
“Henrik possesses a rare combination of scientific expertise and commercial experience. With his many years of diagnostics background, he brings with him tremendous insight and an extensive network of contacts. Henrik is an important piece of the...
2019-11-20 08:20
The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery...
2019-11-20 08:00
The prognostic value of DiviTum was assessed in a prospective study of 103 metastatic breast cancer patients treated from May 2016 until August 2018 at Institut Curie, Paris, with endocrine therapy and the CDK4/6 inhibitor palbociclib. Plasma samples...
2019-11-15 08:00
Otti Bengtsson Gref has a long experience of leading positions in the R&D field in the commercial diagnostic industry. Otti most recently comes from the role as R&D Director at Cavidi. She has held various managerial positions in R&D at IDD...
2019-10-25 11:28
“The renewal of the certificate is important for Biovica as it proves that our quality management system fulfills the global quality requirements. The quality management system is a pre-requisite for market approval in both US and Europe and hence...
2019-10-03 08:45
At the conference, Pontus Nobréus will address how liquid biomarkers can contribute with fundamental information and to a more effective process in the development of oncology drugs. DiviTum® is a cell proliferation biomarker and a valuable...
2019-09-18 08:00
The presentation will be held in English and will be followed by a questions and answers session. Questions can be asked via the telephone conference or in written form via the audiocast. No pre-registration is needed. Participant dial in number DK: +4578150109...
2019-09-18 08:00
Under the agreement, the DiviTum® blood assay will be used to analyze blood samples taken from participants in S0226, which between 2004 and 2009 enrolled 707 postmenopausal women with metastatic breast cancer at 73 hospitals, clinics, and cancer...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects